Dianthus Therapeutics Stock Probability of Future Stock Price Finishing Under 23.36
| DNTH Stock | 23.99 0.16 0.67% |
Dianthus |
Dianthus Therapeutics Target Price Odds to finish below 23.36
The tendency of Dianthus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to 23.36 or more in 90 days |
| 23.99 | 90 days | 23.36 | under 4 |
Based on a normal probability distribution, the odds of Dianthus Therapeutics to drop to 23.36 or more in 90 days from now is under 4 (This Dianthus Therapeutics probability density function shows the probability of Dianthus Stock to fall within a particular range of prices over 90 days) . Probability of Dianthus Therapeutics price to stay between 23.36 and its current price of 23.99 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days the stock has the beta coefficient of 1.58 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Dianthus Therapeutics will likely underperform. Additionally Dianthus Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Dianthus Therapeutics Price Density |
| Price |
Predictive Modules for Dianthus Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dianthus Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dianthus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dianthus Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Dianthus Therapeutics is not an exception. The market had few large corrections towards the Dianthus Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Dianthus Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Dianthus Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.4 | |
β | Beta against Dow Jones | 1.58 | |
σ | Overall volatility | 2.01 | |
Ir | Information ratio | -0.09 |
Dianthus Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Dianthus Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Dianthus Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Dianthus Therapeutics generated a negative expected return over the last 90 days | |
| Dianthus Therapeutics has high historical volatility and very poor performance | |
| Dianthus Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.83 M. Net Loss for the year was (43.55 M) with profit before overhead, payroll, taxes, and interest of 6.42 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Oppenheimer sees upside in Dianthus as CIDP study gains FDA support |
Dianthus Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Dianthus Stock often depends not only on the future outlook of the current and potential Dianthus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dianthus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.2 M | |
| Cash And Short Term Investments | 173.7 M |
Dianthus Therapeutics Technical Analysis
Dianthus Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Dianthus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Dianthus Therapeutics. In general, you should focus on analyzing Dianthus Stock price patterns and their correlations with different microeconomic environments and drivers.
Dianthus Therapeutics Predictive Forecast Models
Dianthus Therapeutics' time-series forecasting models is one of many Dianthus Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Dianthus Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Dianthus Therapeutics
Checking the ongoing alerts about Dianthus Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Dianthus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Dianthus Therapeutics generated a negative expected return over the last 90 days | |
| Dianthus Therapeutics has high historical volatility and very poor performance | |
| Dianthus Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.83 M. Net Loss for the year was (43.55 M) with profit before overhead, payroll, taxes, and interest of 6.42 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Oppenheimer sees upside in Dianthus as CIDP study gains FDA support |
Check out Dianthus Therapeutics Backtesting, Dianthus Therapeutics Valuation, Dianthus Therapeutics Correlation, Dianthus Therapeutics Hype Analysis, Dianthus Therapeutics Volatility, Dianthus Therapeutics History as well as Dianthus Therapeutics Performance. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 7.22 | Revenue Per Share 0.19 | Quarterly Revenue Growth 1.351 | Return On Assets (0.19) | Return On Equity (0.26) |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.